L. Looijenga

Prof. dr. , Groupleader, Managing Director Research, Medical Cell Biologist, Groupleader

Calculated based on number of publications stored in Pure and citations from Scopus
1990 …2023

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Short biography: Leendert Looijenga is Medical Cell Biologist by training (Cum Laude, 1989) and Professor of Translational Patho-Oncology (since 2005, endowed since 2017). He received his PhD in Medical Biology from Erasmus University (Rotterdam) in 1994. Since 1990 he is leading a research group studying translational aspects of Germ Cell Tumors (GCTs), focusing on understanding the pathogenesis and clinical behavior, with the aim to develop informative diagnostic, prognostic and predictive biomarkers. In 2018 he started his activities at the Princess Máxima Center for Pediatric Oncology focusing on pediatric and adolescent and young adult GCT patients, with the mission to improve diagnosis and treatment response, resulting in optimal long-term quality of life. Looijenga has been involved in the testicular GCT patient support group (zaadbalkanker) since its origin in 1996. He received project grants from KWF, NWO/ZonMW (including VIDI) and Industry, accounting for 16 during the last 5 years (57 in total). Leendert Looijenga published multiple papers and book chapters. These include papers in (Cancer) Cell, Nature Reviews, Cell Reports, Genome Biology, European Urology and the Journal of Clinical Oncology. His H-index (August 2022) is 108, with 48,903 citations (26,276 since 2017). Looijenga filed two patents in the last 3 years. Looijenga his field-weighted citation impact in the last 5 years is 7.18. Over 52% of his outputs over that period are in the 10% citation percentile and over 60% of his publication outputs are in the top 10% Journal percentiles (77% top 25%). Over 68% of his primary papers include international collaborations. Looijenga gave 75 invited seminars in the last 5 years. Looijenga his first publication related to platin-resistance of GCTs was in 1999, followed by 15 since then. The major most recent related breakthrough is the 2022 Journal of Clinical Oncology paper.


Professional Information

1990: Junior Scientist Daniel den Hoed Cancer Center Rotterdam

1999: Assistent Professor Academic Hospital Rotterdam/Daniel den Hoed Cancer Center

2005: Professor Translational Patho-Oncology, Erasmus Medical Center, Rotterdam

2014: BKO (Teaching certificate)

2017: Endowed Professor Translational Patho-Oncology, Erasmus Medical Center, Rotterdam

2018: Groupleader Princess Maxima Center, Utrecht

2021: Groupleader (50%) and Managing Director (50%) Princess Maxima Center, Utrecht

2023: Professor of Translational Germ Cell Oncology and Fertility at the UMC Utrecht


Education/Academic qualification

PhD, Pathobiology of germ cell tumors of the adult testis; views and news, Erasmus University Medical Center

Award Date: 9 Nov 1994

Master, Biology, University of Groningen

Award Date: 25 May 1989

External positions

Prof. Translational Patho-Oncology, Erasmus MC University Medical Centre


  • Q Science (General)
  • Embryology
  • Germ cell (tumors)
  • Gonad development and function
  • (Tissue and liquid biopsy) Biomarkers
  • Treatment sensitivity and resistance
  • (in)Fertility and preservation
  • In vitro and in vivo model system
  • (Pediatric) Oncology


Dive into the research topics where L. Looijenga is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or